Home/Filings/4/0000950170-23-031207
4//SEC Filing

MacDonald Brian Richard 4

Accession 0000950170-23-031207

CIK 0001816736other

Filed

Jun 29, 8:00 PM ET

Accepted

Jun 30, 6:29 PM ET

Size

22.5 KB

Accession

0000950170-23-031207

Insider Transaction Report

Form 4
Period: 2023-06-28
MacDonald Brian Richard
Chief Innovation Officer
Transactions
  • Sale

    Common Stock

    2023-06-28$49.24/sh2,247$110,64925,153 total
  • Sale

    Common Stock

    2023-06-28$50.80/sh953$48,41522,300 total
  • Sale

    Common Stock

    2023-06-29$45.49/sh2,230$101,45319,334 total
  • Sale

    Common Stock

    2023-06-29$46.51/sh1,934$89,95217,400 total
  • Sale

    Common Stock

    2023-06-30$46.76/sh+600$28,05812,276 total
  • Sale

    Common Stock

    2023-06-29$44.37/sh736$32,65621,564 total
  • Sale

    Common Stock

    2023-06-28$50.38/sh1,900$95,73023,253 total
  • Sale

    Common Stock

    2023-06-29$47.24/sh200$9,44817,200 total
  • Sale

    Common Stock

    2023-06-30$44.85/sh2,923$131,10214,277 total
  • Sale

    Common Stock

    2023-06-30$45.45/sh1,401$63,67612,876 total
Holdings
  • Common Stock

    (indirect: Held by Son)
    1,096
  • Common Stock

    (indirect: Held by Son)
    1,096
  • Common Stock

    (indirect: Held by Son)
    1,096
Footnotes (12)
  • [F1]The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023.
  • [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.31 to $45.58, inclusiv
  • [F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.56 to $47.00, inclusive.
  • [F12]The Reporting Person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.61 to $49.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (11) to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.61 to $50.59, inclusive.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.62 to $51.235, inclusive.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.87, inclusive.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.94, inclusive.
  • [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.04 to $46.96, inclusive.
  • [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.23 to $47.25, inclusive.
  • [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $45.29, inclusive.

Documents

1 file

Issuer

Disc Medicine, Inc.

CIK 0001816736

Entity typeother

Related Parties

1
  • filerCIK 0001952556

Filing Metadata

Form type
4
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 6:29 PM ET
Size
22.5 KB